{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T05:35:03Z","timestamp":1766208903545,"version":"3.48.0"},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,12,15]]},"DOI":"10.2169\/internalmedicine.5412-25","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T18:07:32Z","timestamp":1750270052000},"page":"3553-3556","source":"Crossref","is-referenced-by-count":0,"title":["Successful Reswitching of Thrombopoietin Receptor Agonists: Two Cases of Immune Thrombocytopenia and Severe Aplastic Anemia"],"prefix":"10.2169","volume":"64","author":[{"given":"Kazuhiro","family":"Itoh","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, NHO Awara National Hospital, Japan"},{"name":"Division of Infection Control and Prevention, University of Fukui Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomi","family":"Otsuki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, NHO Awara National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, NHO Awara National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiyo","family":"Kiriba","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, NHO Awara National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kuwata","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, NHO Awara National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Tsutani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, NHO Awara National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Division of Infection Control and Prevention, University of Fukui Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Mitsuke","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, NHO Awara National Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3: 3829-3866, 2019.","DOI":"10.1182\/bloodadvances.2019000966"},{"key":"2","unstructured":"2. Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al.; the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. Eltrombopag added to immunosuppression in severe aplastic anemia. N Engl J Med 386: 11-23, 2022."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Jang JH, Tomiyama Y, Miyazaki K, et al. Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II\/III, multicentre, open-label study. Br J Haematol 192: 190-199, 2021.","DOI":"10.1111\/bjh.17190"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood 123: 1818-1825, 2014.","DOI":"10.1182\/blood-2013-10-534743"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 27: 424-430, 2009.","DOI":"10.1634\/stemcells.2008-0366"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Cwirla SE, Balasubramanian P, Duffin DJ, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 276: 1696-1699, 1997.","DOI":"10.1126\/science.276.5319.1696"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Khellaf M, Viallard JF, Hamidou M, et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica 98: 881-887, 2013.","DOI":"10.3324\/haematol.2012.074633"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hosokawa K, Yamazaki H, Tanabe M, Imi T, Sugimori N, Nakao S. High-dose romiplostim accelerates hematologic recovery in patients with aplastic anemia refractory to eltrombopag. Leukemia 35: 906-909, 2021.","DOI":"10.1038\/s41375-020-0950-6"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55<sup>-<\/sup>CD59<sup>-<\/sup> blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 107: 1308-1314, 2006.","DOI":"10.1182\/blood-2005-06-2485"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Bussel J, Kulasekararaj A, Cooper N, et al. Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. Semin Hematol 56: 262-278, 2019.","DOI":"10.1053\/j.seminhematol.2019.09.001"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Lakhwani S, Perera M, Fern\u00e1ndez-Fuertes F, et al. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: a retrospective collaborative survey involving 4 Spanish centres. Eur J Haematol 99: 372-377, 2017.","DOI":"10.1111\/ejh.12932"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 367: 11-19, 2012.","DOI":"10.1056\/NEJMoa1200931"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Ghadaki B, Nazi I, Kelton JG, Arnold DM. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion 53: 2807-2812, 2013.","DOI":"10.1111\/trf.12139"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Mah\u00e9vas M, Fain O, Ebbo M, et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol 165: 865-869, 2014.","DOI":"10.1111\/bjh.12888"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. \u010cervinek L, Mayer J, Doubek M. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults. Int J Hematol 102: 7-11, 2015.","DOI":"10.1007\/s12185-015-1793-1"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Gonz\u00e1lez-L\u00f3pez TJ, Pascual C, \u00c1lvarez-Rom\u00e1n MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol 90: E40-E43, 2015.","DOI":"10.1002\/ajh.23900"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Desmond R, Townsley DM, Dunbar C, Young NS. Eltrombopag in aplastic anemia. Semin Hematol 52: 31-37, 2015.","DOI":"10.1053\/j.seminhematol.2014.10.002"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Bao W, Bussel JB, Heck S, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 116: 4639-4645, 2010.","DOI":"10.1182\/blood-2010-04-281717"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Nishimoto T, Numajiri M, Nakazaki H, Okazaki Y, Kuwana M. Induction of immune tolerance to platelet antigen by short-term thrombopoietin treatment in a mouse model of immune thrombocytopenia. Int J Hematol 100: 341-344, 2014.","DOI":"10.1007\/s12185-014-1661-4"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/24\/64_5412-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T03:39:46Z","timestamp":1766201986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/24\/64_5412-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":19,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5412-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"article-number":"5412-25"}}